Does Trulicity cause hair loss? It is a question increasingly raised by patients using this once-weekly GLP-1 receptor agonist for type 2 diabetes management. Trulicity (dulaglutide) is licensed in the UK by the MHRA and has a well-established safety profile, yet some users report increased hair shedding during treatment. This article examines what the current evidence shows, explores why hair loss may occur indirectly, outlines when to seek medical advice, and explains how to report suspected side effects through the MHRA Yellow Card scheme.

Trulicity and Hair Loss: What the Evidence Shows

Hair loss is not listed as a recognised side effect of Trulicity in its UK SmPC or EMA EPAR, and there is no established direct pharmacological mechanism by which dulaglutide causes hair follicle disruption.

Experiencing these side effects? Our pharmacists can help you navigate them →

Trulicity (dulaglutide) is a GLP-1 receptor agonist used in the management of type 2 diabetes in adults. It works by mimicking the action of the naturally occurring hormone glucagon-like peptide-1, stimulating insulin release, suppressing glucagon, and slowing gastric emptying. It is administered as a once-weekly subcutaneous injection and is licensed in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Dulaglutide is not currently licensed for weight management in the UK.

At present, hair loss (alopecia) is not listed as a recognised side effect of Trulicity in its official UK Summary of Product Characteristics (SmPC), as published on the electronic Medicines Compendium (eMC), nor in the European Medicines Agency (EMA) European Public Assessment Report (EPAR) for dulaglutide. There is no established, direct pharmacological mechanism by which dulaglutide would cause hair follicle disruption or accelerated hair shedding.

However, a number of patients using GLP-1 receptor agonists have reported noticing increased hair shedding, particularly in the context of significant or rapid weight loss. It is worth noting that alopecia has been reported as an adverse effect in clinical trials of obesity-dose semaglutide (Wegovy) — a related GLP-1 receptor agonist — and is listed in the Wegovy UK SmPC. This is thought to reflect the physiological consequences of rapid weight loss rather than a direct drug effect, and does not establish a class effect applicable to dulaglutide.

It is important to distinguish between a direct drug-induced effect and hair loss that may be secondary to physiological changes associated with treatment, such as nutritional shifts or metabolic stress. The current evidence does not support a direct causal link between Trulicity and hair loss, but the topic warrants careful consideration given patient-reported experiences. Telogen effluvium — a temporary, diffuse form of hair shedding — typically begins 2–3 months after a physiological trigger and, once the trigger is addressed, most people see hair regrowth over approximately 6–9 months.

Not sure if this is normal? Chat with one of our pharmacists →

Recognised Side Effects of Trulicity (Dulaglutide)

The most common side effects of Trulicity are gastrointestinal — including nausea, vomiting, and diarrhoea — along with hypoglycaemia when combined with insulin or sulphonylureas; alopecia does not appear in any adverse event category.

Understanding the established side effect profile of Trulicity helps to contextualise concerns about hair loss. According to the MHRA-approved dulaglutide SmPC, the most commonly reported adverse effects include:

• Gastrointestinal symptoms: nausea, vomiting, diarrhoea, abdominal pain, and reduced appetite — these are the most frequently reported and are typically most pronounced when starting treatment or increasing the dose

• Hypoglycaemia: particularly when used in combination with insulin or sulphonylureas

• Injection site reactions: redness, itching, or mild discomfort at the injection site

• Heart rate: a small mean increase in resting heart rate has been observed in clinical trials; the clinical significance of this in individual patients should be discussed with a prescriber

• Gallbladder disorders: including cholelithiasis (gallstones) and cholecystitis, which have been reported with dulaglutide

Less commonly, pancreatitis has been reported with GLP-1 receptor agonists as a class. Patients should be advised to seek urgent medical attention if they experience severe, persistent abdominal pain. If pancreatitis is suspected, dulaglutide should be discontinued and not restarted, in line with SmPC guidance. Renal impairment has also been noted in association with dehydration secondary to gastrointestinal side effects.

Notably, alopecia does not appear in the common, uncommon, or rare adverse event categories within the Trulicity SmPC. This does not entirely rule out an association at the individual patient level, but it does indicate that hair loss has not been identified as a consistent, drug-attributable effect across clinical trial populations or post-marketing surveillance data to date.

This is not a complete list of side effects. Patients should consult the Patient Information Leaflet (PIL) or the full SmPC, available via the eMC (medicines.org.uk), for comprehensive safety information, and discuss any concerns with their GP, pharmacist, or diabetes care team.

Why Some People May Notice Hair Loss on GLP-1 Medicines

Hair shedding on GLP-1 medicines is most likely telogen effluvium, triggered indirectly by rapid weight loss, reduced caloric intake, or nutritional deficiencies rather than a direct effect of dulaglutide.

Although Trulicity itself is not directly implicated in causing hair loss, there are plausible indirect reasons why some individuals may experience increased hair shedding whilst taking it — or other GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy).

Telogen effluvium is the most likely explanation. This is a well-recognised, temporary form of diffuse hair shedding that occurs when the body experiences significant physiological stress. It typically begins 2–3 months after the triggering event and, once the underlying cause is addressed, hair usually regrows over approximately 6–9 months. Common triggers include rapid weight loss, caloric restriction, nutritional deficiencies, and metabolic changes — all of which can occur in patients who respond strongly to GLP-1 therapy.

Key contributing factors may include:

• Rapid or significant weight loss: Losing weight quickly can disrupt the normal hair growth cycle, pushing more follicles into the resting (telogen) phase simultaneously. This mechanism is supported by reports of alopecia in obesity-dose semaglutide trials, where significant weight reduction was achieved

• Reduced dietary intake: Appetite suppression from Trulicity may lead to lower consumption of protein, iron, and zinc — nutrients essential for healthy hair growth

• Underlying metabolic conditions: Poorly controlled type 2 diabetes, thyroid dysfunction, or anaemia — conditions that may coexist in patients taking Trulicity — can independently contribute to hair thinning

• Psychological stress: Adjusting to a new diagnosis or treatment regimen can itself act as a physiological stressor

Telogen effluvium is generally self-limiting. Nutritional optimisation and a gradual, sustainable approach to weight loss may help reduce the risk.

When to Speak to Your GP or Prescriber

Patients should contact their GP if hair loss is significant, worsening, patchy, or accompanied by symptoms such as fatigue or cold intolerance, which may indicate an underlying thyroid disorder or nutritional deficiency.

Whilst hair shedding associated with Trulicity treatment is unlikely to represent a serious medical emergency, there are circumstances in which it is important to seek professional advice. Patients should contact their GP or diabetes care team if they notice:

• Significant or sudden hair loss that appears to be worsening over several weeks

• Hair loss accompanied by other symptoms such as fatigue, cold intolerance, unexplained weight changes, or skin changes, which may suggest an underlying thyroid disorder or other systemic condition

• Signs of nutritional deficiency, including brittle nails, mouth ulcers, or persistent fatigue, particularly if appetite has been markedly reduced since starting Trulicity

• Hair loss that is patchy or localised, which may indicate alopecia areata — an autoimmune condition unrelated to medication

• Scalp inflammation, scaling, pain, or scarring, which are red-flag features that warrant prompt dermatology review

• Any concerns about whether Trulicity is the right treatment, or if side effects are significantly affecting quality of life

A GP can arrange appropriate investigations. In UK primary care, first-line blood tests for diffuse hair shedding typically include a full blood count (FBC), ferritin, and thyroid-stimulating hormone (TSH). Vitamin D may also be assessed, as deficiency is common and can contribute to hair shedding. Tests such as zinc, vitamin B12, and folate are generally reserved for cases where there is a specific clinical indication based on history or examination findings.

It is important not to stop Trulicity without medical advice, as this may affect blood glucose control. Your prescriber can help weigh the benefits and risks and, if necessary, consider alternative treatment options in line with NICE guidance on type 2 diabetes management (NG28).

Managing Hair Loss Alongside Trulicity Treatment

Ensuring adequate protein and micronutrient intake, aiming for gradual weight loss, and using gentle hair care practices are the key strategies for managing hair shedding whilst continuing Trulicity treatment.

For patients who are experiencing hair shedding whilst taking Trulicity, a practical and measured approach can help address the issue without compromising diabetes management. The following strategies may be beneficial:

Nutritional support

• Ensure adequate protein intake (at least 0.8–1 g per kg of body weight daily), as protein is fundamental to hair structure

• Consider a review with a registered dietitian, particularly if appetite suppression has led to significantly reduced food intake

• Address any confirmed nutritional deficiencies — iron and ferritin are particularly relevant to hair health and can be assessed via blood tests. Supplementation should only be undertaken if a deficiency has been identified, and under appropriate medical supervision

• Biotin (vitamin B7): routine testing or supplementation is not recommended unless a deficiency is confirmed. Importantly, the MHRA has issued a Drug Safety Update warning that high-dose biotin supplements can interfere with a range of immunoassay-based laboratory tests, potentially causing misleading results. If you are taking biotin supplements, inform your clinician before any blood tests are taken

Lifestyle measures

• Aim for a gradual, sustainable rate of weight loss (typically 0.5–1 kg per week) rather than very rapid reduction, which is more likely to trigger telogen effluvium

• Manage stress where possible, as psychological stress can compound hair shedding

• Use gentle hair care practices — avoid excessive heat styling, tight hairstyles, or harsh chemical treatments during periods of increased shedding

Medical review

• A dermatology referral may be considered if hair loss is severe, persistent beyond six months, associated with scalp inflammation or scarring, or does not fit the typical pattern of telogen effluvium

In most cases, hair shedding associated with weight loss or metabolic change is temporary. Most people can expect hair regrowth over approximately 6–9 months once the underlying trigger is addressed. Reassurance, nutritional optimisation, and close monitoring are usually sufficient.

MHRA Guidance and Reporting Side Effects in the UK

Patients and healthcare professionals should report suspected side effects of Trulicity, including hair loss, via the MHRA Yellow Card scheme online at yellowcard.mhra.gov.uk or through the Yellow Card app.

The MHRA is the UK regulatory authority responsible for monitoring the safety of medicines, including Trulicity. Post-marketing surveillance plays a vital role in identifying adverse effects that may not have been apparent during clinical trials, particularly rare or delayed reactions. Whilst hair loss is not currently listed as a recognised side effect of dulaglutide in its UK SmPC, the MHRA continues to review emerging data as real-world evidence accumulates.

Patients and healthcare professionals in the UK are encouraged to report any suspected side effects — including hair loss — through the Yellow Card scheme, the MHRA's pharmacovigilance reporting system. Reports can be submitted:

• Online at: yellowcard.mhra.gov.uk

• Via the Yellow Card app, available on iOS and Android

• Through a GP, pharmacist, or nurse, who can submit a report on a patient's behalf

Reporting suspected side effects, even when a causal link is uncertain, is important. It contributes to the national evidence base and helps the MHRA identify patterns that may prompt further investigation or updates to prescribing guidance. Healthcare professionals are reminded that all suspected adverse drug reactions (ADRs) should be reported, not only those considered definitively drug-related.

Patients taking Trulicity should be reassured that the medicine has a well-established safety profile supported by extensive clinical trial data and ongoing post-marketing review. The full Patient Information Leaflet (PIL) and SmPC for Trulicity are available via the eMC at medicines.org.uk. Any concerns about side effects should be discussed openly with a GP, diabetes specialist nurse, or pharmacist, who can provide personalised guidance in line with current NICE (NG28) and MHRA recommendations.

Frequently Asked Questions